title: Survival and reproductive function after treatment of malignant germ cell ovarian tumors.
abstract: OBJECTIVE
  Germ cell ovarian tumors are curable. The possible sequelae of chemotherapy on long-term survivors are still unknown, but these patients may expect normal lives. The aim of this study was to evaluate the outcome and reproductive function in a population of women treated since 1982.
  
  
  METHODS
  Between 1982 and 1996, 169 women with malignant germ cell ovarian tumors were seen (70 dysgerminomas, 28 endodermal sinus tumors, 24 mixed tumors, and 47 immature teratomas). Seventy-one had advanced or recurrent disease. Fertility-sparing surgery was performed in 138 (81%) women, 81 of whom received postoperative chemotherapy.
  
  
  RESULTS
  With a median follow-up of 67 months, the survival rate was 94% for dysgerminoma, 89% for endodermal sinus tumors, 100% for mixed types, and 98% for immature teratoma. For women who were treated conservatively, the survival rate was 98%, 90%, 100%, and 100%, respectively. Two women had adnexal recurrences, and both received salvage treatment. After treatment, all but one postpubertal woman had recovery of menses within 9 months. During follow-up, 12 untreated and 20 treated patients had 55 conceptions. We recorded 40 pregnancies at term, six terminations, and nine miscarriages. Four malformations were observed: one in 14 conceptions of patients who had not received chemotherapy and three in 41 conceptions of treated patients.
  
  
  CONCLUSIONS
  Irrespective of subtype and stage, conservative surgery should become the standard approach to treating most patients with malignant ovarian germ cell tumors. Fertility seems to be only marginally affected by treatments. Miscarriages are in the expected range for the general population. The malformation rate is slightly higher than in the general population, but no significant difference was seen between patients who did and did not receive chemotherapy.
authors.affiliation: Department of Obstetrics and Gynecology, San Gerardo Hospital of Monza, University of Milano, Bicocca, Italy. gzanetta@iol.it
authors.forename: G
authors.initials: G
authors.lastname: Zanetta
authors.forename: C
authors.initials: C
authors.lastname: Bonazzi
authors.forename: M
authors.initials: M
authors.lastname: Cantù
authors.forename: S
authors.initials: S
authors.lastname: Binidagger
authors.forename: A
authors.initials: A
authors.lastname: Locatelli
authors.forename: G
authors.initials: G
authors.lastname: Bratina
authors.forename: C
authors.initials: C
authors.lastname: Mangioni
mesh_terms: D000293:Adolescent; D000328:Adult; D017024:Chemotherapy, Adjuvant; D002648:Child; D000013:Congenital Abnormalities / Q000209:etiology; D005260:Female; D005298:Fertility; D006801:Humans; D009373:Neoplasms, Germ Cell and Embryonal / Q000401:mortality* / Q000503:physiopathology* / Q000628:therapy; D010051:Ovarian Neoplasms / Q000401:mortality* / Q000503:physiopathology* / Q000628:therapy; D011247:Pregnancy; D011256:Pregnancy Outcome; D015996:Survival Rate